

## Exploring the Antimicrobial Properties potential of *Lactobacillus Plantarum* Postbiotic Engineering k-016

Noraina Muhamad Zakuan<sup>1,2</sup>, Wong jest Phia<sup>4</sup>, Latifah Saiful Yazan<sup>1,2</sup>

<sup>1</sup>Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

<sup>2</sup>Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

<sup>3</sup>Department of Bioprocess Technology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

<sup>4</sup>Westwood Clinic, Pj Midtown, Sekseyn 13 Petaling Jaya, Selangor, Malaysia.

### Abstract

Bacteria and their metabolites are shown to be a potential therapeutic agent for cancer treatment. Much attention has been directed to Lactic acid bacteria (LAB) which exhibits several killing mechanisms via invasion and colonization of solid tumors. Discovery of the characteristics of postbiotic metabolites that exert the same probiotic effects has attracted immense attention towards anti-cancer effect. It is known that LAB improves health and composition of microbiota in the gut. Supplementation of LAB is proven to enhance the host immunity and modulation of the immune system to fight diseases including cancers. *Lactobacillus plantarum* is the LAB species isolated from Malaysian fermented food, *Tapai Ubi* which capable of producing bioactive metabolic products. In this review, the properties will be discussed including anti-microbial, anti-cancer and immunomodulatory effects. Overall, it would be beneficial to discover the potential effects of UL4-PPM to possibly serve as an alternative treatment for cancer.

**Keywords:** Cancer, Lactic acid bacteria, Metabolites, Immunity

### Introduction

Cancer is an emerging public health problem in developing countries and is the second most common disease leads to death in the United States. It is estimated that about 1,685,210 cases were expected in 2016 which is approximately over 4,600 new cancer cases were diagnoses each day worldwide (1). Colorectal cancer (CRC) is the third most commonly diagnosed cancer among both men and women in the United States. In Malaysia, colorectal cancer is the second most common cancer in both males and females in 2016. It is estimated that 2600 cases in men while 2000 cases in women were reported in Malaysia with 1300 and 1000 of mortality rate, respectively (2). Mortality due to colorectal cancer is increasing and has been reported as the fourth leading cause of cancer death worldwide (3). However, the reported incidence of colorectal cancer is higher in developed Asian countries such as Japan, South Korea, and Singapore compared to Malaysia and other developing Asian countries (4). Diet has been shown to reduce CRC incidence by approximately 80% as it has multiple effects which could alter the metabolome or metabolites composition of the host (5).

Despite the advancement in cancer discovery and therapy, cancer has remained a major burden of disease worldwide leading to high incidence of deaths. Furthermore, adverse side effects are generally associated with the currently available chemotherapeutic agents due to unspecific toxicity towards normal cells. Probiotics including LAB have been reported to promote health and can be a potential preventive and therapeutic agent (6). Probiotics are live microbial food supplements with the ability to beneficially affect the gut microbiota by attributing a variety of immunological and metabolic parameters. There are several well-

defined mechanisms including alteration of normal microbial ecosystem composition, maintenance of the functions of gut lumen epithelial barrier, and modulation of mucosal and systemic immune responses of the host (7, 8). In addition, probiotics and their metabolite products, postbiotics, have been proposed as food supplements to promote health and intestinal composition, as well as therapeutic agents in inflammatory bowel disease (IBD) (9).

Recently, the potential of metabolite product synthesized from probiotics in exerting the probiotic effects outside living cells either using metabolite combinations (10) or in combination with other prebiotics has drawn a lot of attention (11). Metabolites have advantages in term of logistics as it is more stable as well as have a wider application in food industries and as feed additives in livestock industries (12). Metabolites from dietary sources have been shown to affect the metabolism of the whole body by direct or indirect interaction with intestinal mucosa from the luminal side (13).

In this review article, the effects of proteinaceous postbiotic metabolite (PPM) produced by *Lactobacillus plantarum* namely afterward as UL4-PPM on anti- microbial, immunomodulatory and anti-carcinogenic properties will be discussed accordingly.

### **Proteinaceous Postbiotic Metabolite From *Lactobacillus plantarum* I-UL4 (PPM-UL4)**

LAB is abundantly present in fermented foods, vegetation, gastrointestinal (GI), oral cavity, and urogenital tract and are commonly associated with several health-promoting elements (8). The ability of LAB to serve as a food preservative is due to the production of anti-microbial metabolites by targeting cell wall or membrane of the organisms such as organic acids and bacteriocins (14). Bacteriocins such as pyocin, colicin and microcin are one of the inhibitory metabolites produced by LAB consisting of amino acids that essentially play a role as to prevent the growth of competing microorganisms, and have been proven to also possess antineoplastic activity (15).

*Lactobacillus plantarum* I-UL4 is one of the LAB species isolated from Malaysian fermented food, Tapai Ubi (16) which has the ability to produce bioactive metabolic compounds termed as postbiotics. UL4-PPM is a postbiotics or metabolite produced by *Lactobacillus plantarum* which is believed to exert the probiotic effects without living cells (10, 17). To date, not much study has been done on the postbiotics, which are metabolite products from the probiotics in cancer- related study since it has been majorly described that LAB act as anti-cancer agent by modulating immune responses in *in vitro* and *in-vivo* studies (18-20).

### **Antimicrobial Properties of PPM-UL4**

A few studies have shown that UL4-PPM encouraged the growth, reduced plasma cholesterol and enhanced the population of indigenous LAB in the intestine and faeces of rats (12). It is associated with a reduction of lowered faecal pH and faecal *Enterobacteriaceae* counts after supplementation with UL4- PPM (12, 16, 21). Modler et al. (22) suggested that reduction in intestinal pH may influenced the progression of large-bowel cancer by preventing the growth of putrefactive bacteria in the gut.

UL4-PPM could be a potential alternative for antibiotic growth promoters (AGPs) as a study conducted in broilers shown that UL4-PPM improved growth performance, LAB count and the concentration of fecal volatile fatty acid, while reducing in the number of *Enterobacteriaceae* (17). In fact, it could be beneficial as some pathogenic bacteria are resistant to numerous antimicrobial agents and potentially lethal when transmitted to humans (23). Anti-microbial properties of UL4-PPM are mainly due to its bactericidal and bacteriostatic effects that can kill pathogenic bacteria in gastrointestinal microflora (17). Report have also shown that increased in villi surface would increase nutrient absorption in small intestine (24).

### **Immunomodulatory And Anti- Carcinogenic Attributes By PPM-UL4**

There are several established drugs for standard first line therapy for CRC such as irinotecan, oxaliplatin and cetuximab. Nevertheless, the drugs have various adverse side effects. Therefore, much attention has been focused on the development of natural product-based anticancer agents that have the advantages as they are believed to have lesser side effects. LAB was found to improve gastrointestinal microbial population (25),

exert antimicrobial activities and anti-carcinogenic properties(26). For example, azurin is a well-characterized bacteriocin discovered to exhibit cytostatic and apoptotic effect against human colon cancer cells (27). In addition, colicins which are metabolites produced by *Escherichia coli* has been shown to induce cell death in tumor cells by targeting the proteins located on the outer surface of the cells through antibody recognition (28, 29). Thus, these bacteriocins are believed to specifically target tumor cells (30). The anti-cancer activities of UL4-PPM towards a breast cancer cell line has been reported in 2015 (31). The similar properties have been proposed for LAB mediated activation of immune response and metabolic activity in colon cancer cells (32). Even though several studies have clearly demonstrated the chemopreventive effects of dietary supplements of LAB against the development of colon cancer (33-35), however the chemopreventive and inhibitory effects of postbiotics or metabolite products from probiotics on colon cancer is very limited. Recently, probiotic metabolites have been shown to affect various functions at the cellular and molecular level including the initiation and progression of colon cancer which they may lead and regulate various metabolic signaling pathways. Signaling pathway involve are crucially responsible for cell proliferation, invasion, apoptosis, inflammation, angiogenesis, and ultimately cancer metastasis (13, 35). A few evidences have demonstrated that metabolites from probiotic cultures could reduce cell proliferation of human colon cancer cells (36, 37). A study has shown that the colorectal cancer severity in azoxymethane-induced rats could be reduced substantially when treated with UL4-PPM in drinking water (38). In this study, treatment with UL4-PPM reduced the total number of aberrant crypt foci (ACF) and crypt multiplicity, the incidence of tumor, adenoma and adenocarcinoma, with decreased expression of  $\beta$ -catenin, indicating the reduction in the severity of colon cancer in animal colon cancer model. Modulation of microbial environment and several compositions of the gut contribute to a better health status and providing beneficial effects to the host. Probiotic was found to reduce an inflammation in patients with gastrointestinal diseases (39). It has been demonstrated that tumor development and cancer metastasis may commonly occur in immunocompromised people. Thus, stimulation of the immune system may enhance host defense towards tumor cells which is also believed to be one of the most important mechanisms to treat the disease. UL4-PPM also has the ability to enhance the level of several cytokines or interleukins which are IFN- $\gamma$ , TNF- $\alpha$ , IL-12 and IL-5 in serum and immune organs (spleen and thymus) that are crucially involve in the inhibition of colon carcinogenesis (38). Immunomodulatory activities of probiotics by regulating the production of anti- or pro-inflammatory interleukins (IL) resulted in the prevention of excessive immune response in inflammatory bowel diseases (40). Therefore, it is postulated that UL4-PPM may exhibit antineoplastic activity due to its immunomodulatory properties in the host.

## Conclusion

UL4-PPM, the metabolites produced by *L. plantarum*, has shown to exert anti-microbial, immunomodulatory and anti-carcinogenic properties in *in vitro* and *in-vivo* studies. Promisingly, UL4-PPM can be developed as a potential agent in prevention and treatment of CRC.

## References

1. Siegel R, Miller K, Jemal A. Cancer statistics, 2017 CA: A Cancer Journal for Clinicians. 2017; 67(1): 7–30.
2. Hassan MRA, Ismail I, Suan MAM, Ahmad F, Khazim WKW, Othman Z, et al. Incidence and mortality rates of colorectal cancer in Malaysia. Epidemiology and Health. 2016;38.
3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67(3):177-193.
4. Sung J, Ng S, Chan F, Chiu H, Kim H, Matsuda T, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64(1):121-32.
5. Singh B, Mukesh M, Sodhi M. Nutrigenomics, metabolomics and metabonomics: emerging faces of molecular genomics and nutrition. Metabolomics: Metabolites, Metabonomics and Analytical Technologies Hauppauge, NY: Nova Science Publishers, Inc. 2011:201-13.
6. Klaenhammer TR, Kleerebezem M, Kopp MV, Rescigno M. The impact of probiotics and prebiotics on the immune system. Nature Reviews Immunology. 2012;12(10):728-34.
7. Licciardi PV, Wong S-S, Tang ML, Karagiannis TC. Epigenome targeting by probiotic metabolites. Gut pathogens. 2010;2(1):24.

8. Oelschlaeger TA. Mechanisms of probiotic actions—a review. *International Journal of Medical Microbiology*. 2010;300(1):57-62.
9. Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G, et al. Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. *Gut*. 2012;gutjnl-2011-300971.
10. Thanh N, Loh TC, Foo HL, Hair-Bejo M, Azhar B. Effects of feeding metabolite combinations produced by *Lactobacillus plantarum* on growth performance, faecal microbial population, small intestine villus height and faecal volatile fatty acids in broilers. *British poultry science*. 2009;50(3):298- 306.
11. Kareem KY, Loh TC, Foo HL, Akit H, Samsudin AA. Effects of dietary postbiotic and inulin on growth performance, IGF1 and GHR mRNA expression, faecal microbiota and volatile fatty acids in broilers. *BMC Veterinary Research*. 2016;12(1):163.
12. Loh T, Chong S, Foo H, Law F. Effects on growth performance, faecal microflora and plasma cholesterol after supplementation of spray-dried metabolite to postweaning rats. *Czech Journal Animal Science*. 2009;54(1):10-6.
13. Kumar M, Nagpal R, Verma V, Kumar A, Kaur N, Hemalatha R, et al. Probiotic metabolites as epigenetic targets in the prevention of colon cancer. *Nutrition reviews*. 2013;71(1):23-34.
14. O'sullivan L, Ross R, Hill C. Potential of bacteriocin- producing lactic acid bacteria for improvements in food safety and quality. *Biochimie*. 2002;84(5):593- 604.
15. Cornut G, Fortin C, Soulières D. Antineoplastic properties of bacteriocins: revisiting potential active agents. *American journal of clinical oncology*. 2008;31(4):399-404.
16. Foo H, Loh T, Lai P, Lim Y, Kufli C, Rusul G. Effects of adding *Lactobacillus plantarum* I-UL4 metabolites in drinking water of rats. *Pakistan Journal of Nutrition*. 2003;2(5):283-8.
17. Loh TC, Thanh NT, Foo HL, HAIR□BEJO M, Azhar BK. Feeding of different levels of metabolite combinations produced by *Lactobacillus plantarum* on growth performance, fecal microflora, volatile fatty acids and villi height in broilers. *Animal Science Journal*. 2010;81(2):205-14.
18. del Carmen S, de LeBlanc AdM, Levit R, Azevedo V, Langella P, Bermúdez-Humarán LG, et al. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. *International Immunopharmacology*. 2017;42:122-9.
19. Chang C-K, Wang S-C, Chiu C-K, Chen S-Y, Chen Z-T, Duh P-D. Effect of lactic acid bacteria isolated from fermented mustard on immunopotentiating activity. *Asian Pacific Journal of Tropical Biomedicine*. 2015;5(4):281-6.
20. Kwak S-H, Cho Y-M, Noh G-M, Om A-S. Cancer preventive potential of kimchi lactic acid bacteria (*Weissella cibaria*, *Lactobacillus plantarum*). *Journal of cancer prevention*. 2014;19(4):253-8.
21. Loh T, Harun H, Foo H, Law F. Effects Of Feeding Spraydried Metabolite Of *Lactococcus Lactis* Subsp. *Lactis*-RW18 In Postweaning Rats. *International Journal of Probiotics and Prebiotics*. 2008;3(1):1.
22. Modler HW, McKellar R, Yaguchi M. Bifidobacteria and bifidogenic factors. *Canadian Institute of Food Science and Technology Journal*. 1990;23(1):29- 41.
23. Chesson A. Phasing out antibiotic feed additives in the EU: worldwide relevance for animal food production. Barug, D, DeJong, J, Kies, AK, Verstegen, MWA, *Antimicrobial Growth Promoters: Where Do We Go from Here* Wageningen Academic Publications, Wageningen. 2006:69-81.
24. Miles R, Butcher G, Henry P, Littell R. Effect of antibiotic growth promoters on broiler performance, intestinal growth parameters, and quantitative morphology. *Poultry Science*. 2006;85(3):476-85.
25. Tannock GW, Fuller R, Smith S, Hall M. Plasmid profiling of members of the family Enterobacteriaceae, lactobacilli, and bifidobacteria to study the transmission of bacteria from mother to infant. *Journal of Clinical Microbiology*. 1990;28(6):1225-8.
26. Fernandes CF, Shahani KM. Anticarcinogenic and immunological properties of dietary lactobacilli. *Journal of Food Protection®*. 1990;53(8):704-10.
27. Shaikh F, Abhinand P, Rangunath P. Identification & Characterization of *Lactobacillus salavarius*



- bacteriocins and its relevance in cancer therapeutics. *Bioinformation*. 2012;8(13):589.
28. Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. *Technology in Cancer Research & Treatment*. 2005;4(4):375-91.
  29. Johannes L, Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. *Gene Therapy*. 2005;12(18):1360-8.
  30. Lancaster LE, Wintermeyer W, Rodnina MV. Colicins and their potential in cancer treatment. *Blood Cells, Molecules, and Diseases*. 2007;38(1):15-8.
  31. Tan HK, Foo HL, Loh TC, Alitheen M, Banu N, Abdul Rahim R. Cytotoxic effect of proteinaceous postbiotic metabolites produced by *Lactobacillus plantarum* I-UL4 cultivated in different media composition on MCF-7 breast cancer cell. *Malaysian Journal of Microbiology*. 2015;11(2):207-14.
  32. Liong M-T. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. *International Journal of Molecular Sciences*. 2008;9(5):854-63.
  33. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. *Microbes and Infection*. 2000;2(6):681-6.
  34. Yamazaki K, Tsunoda A, Sibusawa M, Tsunoda Y, Kusano M, Fukuchi K, et al. The effect of an oral administration of *Lactobacillus casei* strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. *Oncology Reports*. 2000;7(5):977-82.
  35. Kumar M, Kumar A, Nagpal R, Mohania D, Behare P, Verma V, et al. Cancer-preventing attributes of probiotics: an update. *International Journal of Food Sciences and Nutrition*. 2010;61(5):473-96.
  36. Lee DK, Jang S, Kim MJ, Kim JH, Chung MJ, Kim KJ, et al. Anti-proliferative effects of *Bifidobacterium adolescentis* SPM0212 extract on human colon cancer cell lines. *BMC Cancer*. 2008;8(1):310.
  37. Ma EL, Choi YJ, Choi J, Pothoulakis C, Rhee SH, Im E. The anticancer effect of probiotic *Bacillus polyfermenticus* on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. *International Journal of Cancer*. 2010;127(4):780-90.
  38. Zakuan NM. Potential Anti-cancer Properties of Bacteriocin UL4 from *Lactobacillus Plantarum* in Rats Induced with Colon Cancer: Universiti Putra Malaysia; 2011.
  39. Guandalini S. Use of *Lactobacillus-GG* in paediatric Crohn's disease. *Digestive and Liver Disease*. 2002;34:S63-S5.
  40. Dimitrovski D, Cencič A, Winkelhausen E, Langerholc T. *Lactobacillus plantarum* extracellular metabolites: In vitro assessment of probiotic effects on normal and cancerogenic human cells. *International Dairy Journal*. 2014;39(2):293-300.